The Role of Methyltransferase Inhibitors in the Management of the Myelodysplastic Syndromes

Lu L.W. , Chiang G.H. , Medina D. Drug effects on nucleic acid modification. I. A specific effect of 5-azacytidine on mammalian transfer RNA methylation in vivo. Biochem Biophys Res Commun. 1976; 68: 1094–1101.

Decitabine: 2′-deoxy-5-azacytidine, Aza dC, DAC, dezocitidine, NSC 127716. Drugs R D. 2003; 4: 179–184.

Burchenal J.H. , Carter S.K. New cancer chemotherapeutic agents. Cancer. 1972; 30: 1639–1646.

Massimo L. , Comelli A. New drugs for the therapy of acute leukemia [in Italian]. Minerva Med. 1975; 66: 2568–2576.

DeSimone J. , Heller P. , Hall L. 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proc Natl Acad Sci U S A. 1982; 79: 4428–4431.

Ley T.J. , DeSimone J. , Noguchi C.T. 5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood. 1983; 62: 370–380.

Steinberg M.H. Review: the sickle hemoglobinopathies. Genetic analyses of common phenocopies and new molecular approaches to treatment. Am J Med Sci. 1984; 288: 169–174.

Samid D. , Yeh A. , Prasanna P. Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate. Blood. 1992; 80: 1576–1581.

Dean A. , Wu Y.J. , Ley T. Augmentation of hemoglobin synthesis by S-phase specific drugs in the K562 cell line. Prog Clin Biol Res. 1985; 191: 205–216.

Stamatoyannopoulos J.A. , Nienhuis A.W. Therapeutic approaches to hemoglobin switching in treatment of hemoglobinopathies. Annu Rev Med. 1992; 43: 497–521.

Jones P.A. , Taylor S.M. Cellular differentiation, cytidine analogs and DNA methylation. Cell. 1980; 20: 85–93.

Taylor S.M. , Jones P.A. Mechanism of action of eukaryotic DNA methyltransferase: use of 5-azacytosine-containing DNA. J Mol Biol. 1982; 162: 679–692.

Creusot F. , Acs G. , Christman J.K. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-′-deoxycytidine. J Biol Chem. 1982; 257: 2041–2048.

Bird A.P. CpG-rich islands and the function of DNA methylation. Nature. 1986; 321: 209–213.

Bird A. The essentials of DNA methylation. Cell. 1992; 70: 5–8.

Bird A.P. The relationship of DNA methylation to cancer. Cancer Surv. 1996; 28: 87–101.

Uchida T. , Kinoshita T. , Nagai H. Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood. 1997; 90: 1403–1409.

Sheikhha M.H. , Tobal K. , Liu Yin J.A. High level of microsatellite instability but not hypermethylation of mismatch repair genes in therapy-related and secondary acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol. 2002; 117: 359–365.

Chiurazzi P. , Pomponi M.G. , Pietrobono R. Synergistic effect of histone hyperacetylation and DNA demethylation in the reactivation of the FMR1 gene. Hum Mol Genet. 1999; 8: 2317–2323.

Groudine M. , Eisenman R. , Weintraub H. Chromatin structure of endogenous retroviral genes and activation by an inhibitor of DNA methylation. Nature. 1981; 292: 311–317.

Silverman L.R. , Holland J.F. , Weinberg R.S. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia. 1993; 7(suppl 1): 21–29.

Silverman L.R. Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS). Oncologist. 2001; 6(suppl 5): 8–14.

Silverman L.R. , Demakos E.P. , Peterson B.L. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002; 20: 2429–2440.

Kornblith A.B. , Herndon J.E. , Silverman L.R. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002; 20: 2441–2452.

Pinto A. , Zagonel V. 5-Aza-2′-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. Leukemia. 1993; 7(suppl 1): 51–60.

Kantarjian H.M. , O'Brien S.M. , Estey E. Decitabine studies in chronic and acute myelogenous leukemia. Leukemia. 1997; 11(suppl 1): S35–S36.

Wijermans P. , Lubbert M. , Verhoef G. Low-dose 5-aza-2′-deoxy-cytidine, a DNA hypomethylating agent, for the treatment of highrisk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000; 18: 956–962.

Daskalakis M. , Nguyen T.T. , Nguyen C. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood. 2002; 100: 2957–2964.

Farinha N.J. , Shaker S. , Lemaire M. Activation of expression of p15, p73 and E-cadherin in leukemic cells by different concentrations of 5-aza-2′-deoxycytidine (Decitabine). Anticancer Res. 2004; 24: 75–78.